Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus b conjugate vaccine (meningococcal protein conjugate)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PedvaxHIB is a vaccine indicated for the prevention of invasive disease caused by *Haemophilus influenzae* type b in infants and children 2 to 71 months of age. It consists of a highly purified capsular polysaccharide (polyribosylribitol phosphate, PRP) from *Haemophilus influenzae* type b covalently bound to an outer membrane protein complex (OMPC) derived from *Neisseria meningitidis* serogroup B. This conjugation converts the T-independent PRP antigen into a T-dependent antigen, resulting in enhanced antibody response and immunologic memory. The vaccine stimulates the immune system to produce Hib capsule-specific antibodies that destroy the bacterial capsule, making the organism susceptible to immune clearance. Developed and manufactured by Merck Sharp & Dohme Corp., PedvaxHIB is administered intramuscularly as part of routine childhood immunization schedules.
- Brand names
- PedvaxHIBLiquid PedvaxHIB
- Other names
- Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
02
Targets
OmpC (Outer membrane porin C)PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on Haemophilus b conjugate vaccine (meningococcal protein conjugate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus b conjugate vaccine (meningococcal protein conjugate).